Clinical Trial Update: Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study MK-1308-001 evaluating Quavonlimab in combination with Pembrolizumab in advanced solid tumors has completed. Results were posted on 2025-04-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Quavonlimab (MK-1308)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-04-08